EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Klinische Studie (Phase II)VergleichsstudieOpen Access · CC BY 4.0

Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials

Alex Soriano, George R Thompson, Oliver A Cornely iD, Matteo Bassetti, Bart Jan Kullberg, Patrick M Honoré, Hervé Dupont, Jose A Vazquez, Haihui Huang, Yingyuan Zhang, Sara Dickerson, Laura Cox und 1 weitere

Mycoses · 2026-07 · 69 (7)

DOI: 10.1111/myc.70205 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Mycoses, online erschienen am 16.07.2026. Verfasst von Alex Soriano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, CIBERINF, Barcelona, Spain. Hauptthemen laut MEDLINE: Caspofungin, Antifungal Agents, Candidiasis, Invasive, Candidemia. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cidara Therapeutics, Mundipharma Research Limited.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy and safety of rezafungin in invasive candidiasis (IC) and candidaemia was demonstrated in the Phase 2 STRIVE and Phase 3 ReSTORE trials, and an additional cohort of patients in ReSTORE from China (ReSTORE China).

Objectives

This post hoc analysis is the first time that combined data from all double‐blind, randomised Phase 2 and 3 rezafungin trials have been evaluated. Outcomes were comprehensively assessed across a large, diverse population.

Methods

Data were assessed from adults with candidaemia/IC in STRIVE (NCT02734862) and ReSTORE (NCT03667690) (including the China extension cohort) who received weekly rezafungin 400/200 mg or daily caspofungin 70/50 mg for ≤ 4 weeks. Efficacy was assessed in the modified intent‐to‐treat population. Endpoints were Day 30 all‐cause mortality (ACM, primary), mycological response at Days 5 and 14 (secondary) and time to negative blood cultures (TTNBC, secondary). Treatment‐emergent adverse events were assessed in the safety population.

Results

Overall, 372 patients were included (rezafungin 179; caspofungin 193). Day‐30 ACM was 20% (33/161) for rezafungin versus 22% (39/178) for caspofungin (weighted difference, −2.4% [95% confidence interval −11.2 to 6.4]). Day‐5 and Day‐14 mycological eradication rates were 73% and 70% for rezafungin versus 65% and 68% for caspofungin, respectively. Median TTNBC was shorter for rezafungin than for caspofungin (23.1 versus 36.7 h, respectively; p = 0.0073). Adverse‐event profiles were generally similar across treatments.

Conclusions

This pooled analysis of Phase 2 and Phase 3 data, including the China extension cohort, supports the efficacy and safety of rezafungin. Rezafungin was non‐inferior to caspofungin, with earlier mycological eradication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CaspofunginAntifungal AgentsCandidiasis, InvasiveCandidemiaEchinocandinsHumansTreatment OutcomeFemaleChinaDouble-Blind MethodMiddle AgedMaleAdultAged

Stichwörter der Autor:innen

CandidaChinacandidaemiacaspofunginefficacyinvasive candidiasisrezafunginsafety

Substanzen

CaspofunginAntifungal AgentsRezafunginEchinocandins

Autor:innen und Institutionen

  • Department of Infectious Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, CIBERINF, Barcelona, Spain.
  • Department of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, California, USA.
  • The Department of Medical Microbiology and Immunology, University of California Davis, Davis, California, USA.
  • Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine, University of Cologne, Cologne, Germany.
  • Department I of Internal Medicine, Division of Infectious Diseases, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine, University Hospital Cologne, Cologne, Germany.
  • German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.

ORCID-Profile: Oliver A Cornely, Peter G Pappas

Förderung

  • Cidara Therapeutics
  • Mundipharma Research Limited

Zitieren

APA

Soriano, A., Thompson, G. R., Cornely, O. A., Bassetti, M., Kullberg, B. J., Honoré, P. M., Dupont, H., Vazquez, J. A., Huang, H., Zhang, Y., Dickerson, S., Cox, L., & Pappas, P. G. (2026). Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials. Mycoses, 69(7). https://doi.org/10.1111/myc.70205

Vancouver

Soriano A, Thompson GR, Cornely OA, Bassetti M, Kullberg BJ, Honoré PM, et al. Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials. Mycoses. 2026;69(7). doi:10.1111/myc.70205

BibTeX
@article{Soriano2026,
  author = {Soriano, Alex and Thompson, George R and Cornely, Oliver A and Bassetti, Matteo and Kullberg, Bart Jan and Honoré, Patrick M and Dupont, Hervé and Vazquez, Jose A and Huang, Haihui and Zhang, Yingyuan and Dickerson, Sara and Cox, Laura and Pappas, Peter G},
  title = {Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials},
  journal = {Mycoses},
  year = {2026},
  volume = {69},
  number = {7},
  doi = {10.1111/myc.70205}
}
Kostenlos starten →